4DMT to Participate in Upcoming Investor Conferences
Rhea-AI Summary
4D Molecular Therapeutics (FDMT), a late-stage biotechnology company, has announced its participation in two major healthcare investor conferences in May 2025. The company's management will engage in fireside chats at the BofA Securities 2025 Healthcare Conference on May 14 at 2:20 p.m. PT and the RBC Capital Markets 2025 Global Healthcare Conference on May 21 at 9:00 a.m. ET. Management will also be available for one-on-one meetings with investors. Webcasts of both presentations will be accessible through the company's investor relations website for up to one year.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, FDMT declined 5.05%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in May. Members of the management team will also be available for one-on-one meetings.
BofA Securities 2025 Healthcare Conference
| Presentation Date: | Wednesday, May 14, 2025 |
| Presentation Time: | 2:20 p.m. PT |
| Webcast Link: | Webcast |
RBC Capital Markets 2025 Global Healthcare Conference
| Presentation Date: | Wednesday, May 21, 2025 |
| Presentation Time: | 9:00 a.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is FDMT presenting at the BofA Securities Healthcare Conference 2025?
When is FDMT's presentation at the RBC Capital Markets Healthcare Conference 2025?
Where can I access the webcast of FDMT's investor conference presentations?
Will FDMT management be available for one-on-one meetings at the healthcare conferences?
